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Summary In a retrospective study we assessed the outcome of oxcarbazepine (OXC)
monotherapy in a naturalistic setting. We identified all adult patients who had been
treated with OXC at a single neurological outpatient center. A total of 175 patients
were identified, 97 of them used OXC as their first AED (Group I), and 78 as second
monotherapy (Group II), after failure of a previous AED. The 1-year retention rates of
OXC treatment were 91% for Group I and 77% for Group II. Discontinuations were due to
adverse effects in 3 patients (3%) in Group I and in 11 patients (14%) in Group II, and
due to lack of efficacy in 2 patients (2%) in Group I and in 6 patients (8%) in Group II. We
conclude that OXC monotherapy is effective and well tolerated.
# 2004 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.Introduction
Several clinical trials have confirmed the efficacy of
oxcarbazepine (OXC) monotherapy in partial sei-
zures with or without secondary generalization,
and in generalized tonic—clonic seizures.1—6 To
date, long-term experience with OXC has been
reported in only two studies, which included mainly
chronic patients switched over to OXC due to pro-
blems with tolerance or inefficacy of a previous
antiepileptic drug (AED).7,8 In this retrospective
study we assessed the long-term outcome of OXC
monotherapy by determining the retention rate for* Corresponding author. Tel.: +358 3 311611;
fax: +358 3 31164351.
E-mail address: sirpa.rainesalo@pshp.fi (S. Rainesalo).
1059-1311/$ — see front matter # 2004 BEA Trading Ltd. Published
doi:10.1016/j.seizure.2004.10.002the treatment. This parameter represents a compo-
site of both efficacy and tolerance of a drug.Methods
We retrospectively screened all adult epileptic
patients (aged at least 16 years) who attended
the outpatient clinic of the Department of Neurol-
ogy at Tampere University Hospital.
We identified 97 patients (51 men, 46 women)
who had used OXC as first monotherapy (Group I),
and 78 patients (36 men, 42 women, Group II) who
had used OXC as alternative monotherapy. The rea-
sons for shifting from a previous AEDmonotherapy to
OXC were adverse effects in 32 patients (41%),
inadequate efficacy in 21 patients (27%), aby Elsevier Ltd. All rights reserved.
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Figure 1 Retention rate for oxcarbazepine treatment.combination of these causes in 13 patients (17%) and
other reasons in 12 patients (15%).
Cox proportional hazards model was used with
time to discontinuation as the outcome. Follow-up
started at introduction of OXC medication and
ended at discontinuation of treatment or closing
date. Retention rate (i.e. proportion of patients
continuing OXC medication) and its 95% confidence
interval were estimated using the Kaplan—Meyer
method.9 The study was approved by the Ethics
committee of the Tampere University Hospital.Results
Retention rates for Group I were 0.91 (0.83—0.96) at
1 year, 0.91 (0.8S3—0.96) at 3 years, and 0.85 at 5
years, and for Group II 0.77 (0.65—0.85) at 1 year,
0.74 (0.61—0.83) at 3 years and 0.66 at 5 years
(Fig. 1). At least 1-year follow-up data were avail-
able for 68 patients of Group I and for 46 patients of
Group II. At 1 year, 41/68 (60%) of patients of Group IFigure 2 Distribution of patients by theand 10/46 (22%) of Group II remained seizure free
after the start of OXC treatment.
The mean daily maintenance doses of OXC were
840 mg (median 600 mg, range 300—2400 mg) in
Group I and 1040 mg (median 900 mg, range 150—
2400 mg) in Group II.
The number of seizure-free patients with differ-
ent daily doses of OXC is shown in Fig. 2.
OXC treatment was withdrawn in nine of the
cases (9%) in Group I, in two cases due to lack of
efficacy, in three cases due to adverse effects, and
in four cases due to other reasons. In Group II, OXC
was discontinued in 20 cases (26%), in six cases due
to lack of efficacy, in eleven cases due to adverse
effects, and in three cases due to other reasons.Discussion
The outcome of initial OXC monotherapy was favor-
able; the 1-year retention rate was 91%, and 60% of
the previously untreated patients, followed up for
at least one year, remained seizure free while on
OXC. These findings concur with those observed in
clinical trials.2,3 Most of the newly diagnosed
patients used doses which are lower than the recom-
mended target dose range, 900—1200 mg/day.10 In
fact, most of the seizure-free patients were on
doses 900 mg/day, and on the other hand, none
of the patients on doses higher than 1500 mg/day
became seizure free. The safety and tolerance of
first monotherapy with OXC were good; the fre-
quency of discontinuation of treatment due to
adverse effects (3%) was even lower than that
observed in monotherapy trials (3.5—12%).1—3
Only a minority of the patients failing on the first
monotherapy due to inadequate control of seizures
will have a good outcome on the second monother-maintenance dose of oxcarbazepine.
74 S. Rainesalo et al.apy.11 However, many of the patients who have
experienced idiosyncratic reactions or intolerable
adverse effects to a previous AED may have a favor-
able outcome on the substituted monotherapy.11 In
our experience, OXC was efficacious and well tol-
erated in most of the patients who shifted to OXC
after failure of a previous AED. However, the per-
centage of patients who became seizure free (22%)
was much smaller than in patients on initial OXC
monotherapy.
In conclusion, the present retrospective survey of
an unselected outpatient population suggests that
OXC monotherapy is an effective and well tolerated
option for adult patients with partial and general-
ized tonic—clonic seizures. Our findings suggest that
many patients may have an excellent response to
OXC as monotherapy at doses lower than usually
recommended, and that only a limited number
of patients benefit from doses higher than
1500 mg/day.References
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